Inducible Costimulator-C-X-C Motif Chemokine Receptor 3 Signaling is Involved in Chronic Obstructive Pulmonary Disease Pathogenesis

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• Caramori G, Ruggeri P, Di Stefano A, et al. Autoimmunity and COPD: clinical implications. Chest. 2018;153(6):1424–1431. doi:10.1016/j.chest.2017.10.033
   PubMed Web of Science ®Google Scholar
• Zhang MQ, Wan Y, Jin Y, et al. Cigarette smoking promotes inflammation in patients with COPD by affecting the polarization and survival of Th/Tregs through up-regulation of muscarinic receptor 3 and 5 expression. PLoS One. 2014;9(11):e112350. doi:10.1371/journal.pone.0112350
   PubMed Web of Science ®Google Scholar
• Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1(1):e8. doi:10.1371/journal.pmed.0010008
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157(2):316–324. doi:10.1111/j.1365-2249.2009.03965.x
   PubMed Web of Science ®Google Scholar
• Hou J, Sun Y, Hao Y, et al. Imbalance between subpopulations of regulatory T cells in COPD. Thorax. 2013;68(12):1131–1139. doi:10.1136/thoraxjnl-2012-201956
   PubMed Web of Science ®Google Scholar
• Caramori G, Casolari P, Barczyk A, Durham AL, Di Stefano A, Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38(4):497–515. doi:10.1007/s00281-016-0561-5
   PubMed Web of Science ®Google Scholar
• Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? Front Immunol. 2016;7:304. doi:10.3389/fimmu.2016.00304
   PubMed Web of Science ®Google Scholar
• Amatore F, Gorvel L, Olive D. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(2):141–150. doi:10.1080/14712598.2020.1693540
   PubMed Web of Science ®Google Scholar
• Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br J Haematol. 2014;166(3):326–335. doi:10.1111/bjh.12941
   PubMed Web of Science ®Google Scholar
• Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263–266. doi:10.1038/16717
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23(1):515–548. doi:10.1146/annurev.immunol.23.021704.115611
   PubMed Web of Science ®Google Scholar
• Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22(3):326–332. doi:10.1016/j.coi.2010.01.001
   PubMed Web of Science ®Google Scholar
• Peng C, Huggins MA, Wanhainen KM, et al. Engagement of the costimulatory molecule ICOS in tissues promotes establishment of CD8(+) tissue-resident memory T cells. Immunity. 2022;55(1):98–114.e115. doi:10.1016/j.immuni.2021.11.017
   PubMed Web of Science ®Google Scholar
• Panneton V, Chang J, Witalis M, Li J, Suh WK. Inducible T-cell co-stimulator: signaling mechanisms in T follicular helper cells and beyond. Immunol Rev. 2019;291(1):91–103. doi:10.1111/imr.12771
   PubMed Web of Science ®Google Scholar
• Maazi H, Patel N, Sankaranarayanan I, et al. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity. 2015;42(3):538–551. doi:10.1016/j.immuni.2015.02.007
   PubMed Web of Science ®Google Scholar
• Kadri N, Korpos E, Gupta S, et al. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol. 2012;188(7):3138–3149. doi:10.4049/jimmunol.1101390
   PubMed Web of Science ®Google Scholar
• Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity. 2008;28(6):870–880. doi:10.1016/j.immuni.2008.03.018
   PubMed Web of Science ®Google Scholar
• Fonseca VR, Ribeiro F, Graca L. T follicular regulatory (Tfr) cells: dissecting the complexity of Tfr-cell compartments. Immunol Rev. 2019;288(1):112–127. doi:10.1111/imr.12739
   PubMed Web of Science ®Google Scholar
• Vidric M, Bladt AT, Dianzani U, Watts TH. Role for inducible costimulator in control of Salmonella enterica serovar Typhimurium infection in mice. Infect Immun. 2006;74(2):1050–1061. doi:10.1128/IAI.74.2.1050-1061.2006
   PubMed Web of Science ®Google Scholar
• Nouailles G, Day TA, Kuhlmann S, et al. Impact of inducible co-stimulatory molecule (ICOS) on T-cell responses and protection against Mycobacterium tuberculosis infection. Eur J Immunol. 2011;41(4):981–991. doi:10.1002/eji.201040608
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119(19):4430–4440. doi:10.1182/blood-2011-11-392324
   PubMed Web of Science ®Google Scholar
• Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1404–1409. doi:10.1164/rccm.2107139
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015–1026. doi:10.1016/S0140-6736(11)60988-4
   PubMed Web of Science ®Google Scholar
• Chen H, Fu T, Suh WK, et al. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res. 2014;2(2):167–176. doi:10.1158/2326-6066.CIR-13-0155
   PubMed Web of Science ®Google Scholar
• Lord GM, Rao RM, Choe H, et al. T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood. 2005;106(10):3432–3439. doi:10.1182/blood-2005-04-1393
   PubMed Web of Science ®Google Scholar
• Beima KM, Miazgowicz MM, Lewis MD, Yan PS, Huang TH, Weinmann AS. T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem. 2006;281(17):11992–12000. doi:10.1074/jbc.M513613200
   PubMed Web of Science ®Google Scholar
• Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10(6):595–602. doi:10.1038/ni.1731
   PubMed Web of Science ®Google Scholar
• Wikenheiser DJ, Ghosh D, Kennedy B, Stumhofer JS. The costimulatory molecule ICOS regulates host Th1 and follicular Th cell differentiation in response to Plasmodium chabaudi chabaudi AS infection. J Immunol. 2016;196(2):778–791. doi:10.4049/jimmunol.1403206
   PubMed Web of Science ®Google Scholar
• Clay BS, Shilling RA, Bandukwala HS, et al. Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cells. PLoS One. 2009;4(11):e7525. doi:10.1371/journal.pone.0007525
   PubMed Web of Science ®Google Scholar
• Redpath SA, van der Werf N, Cervera AM, et al. ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol. 2013;43(3):705–715. doi:10.1002/eji.201242794
   PubMed Web of Science ®Google Scholar
• Vocanson M, Rozieres A, Hennino A, et al. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol. 2010;126(2):280–289, 289 e281–287. doi:10.1016/j.jaci.2010.05.022
   PubMed Web of Science ®Google Scholar
• Zheng J, Chan PL, Liu Y, et al. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner. PLoS One. 2013;8(12):e82203. doi:10.1371/journal.pone.0082203
   PubMed Web of Science ®Google Scholar
• Chen Q, Mo L, Cai X, et al. ICOS signal facilitates Foxp3 transcription to favor suppressive function of regulatory T cells. Int J Med Sci. 2018;15(7):666–673. doi:10.7150/ijms.23940
   PubMed Web of Science ®Google Scholar
• Landuyt AE, Klocke BJ, Colvin TB, Schoeb TR, Maynard CL. Cutting edge: ICOS-deficient Regulatory T cells display normal induction of Il10 but readily downregulate expression of Foxp3. J Immunol. 2019;202(4):1039–1044. doi:10.4049/jimmunol.1801266
   PubMed Web of Science ®Google Scholar
• Nagase H, Takeoka T, Urakawa S, et al. ICOS(+) Foxp3(+) TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140(3):686–695. doi:10.1002/ijc.30475
   PubMed Web of Science ®Google Scholar
• Kornete M, Sgouroudis E, Piccirillo CA. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. J Immunol. 2012;188(3):1064–1074. doi:10.4049/jimmunol.1101303
   PubMed Web of Science ®Google Scholar
• Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9):1871–1878. doi:10.1084/jem.20100209
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129–138. doi:10.1002/eji.200636435
   PubMed Web of Science ®Google Scholar
• Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol. 2007;37(1):21-23. doi:10.1002/eji.200636929
   Web of Science ®Google Scholar
• Meng ZJ, Wu JH, Zhou M, et al. Peripheral blood CD4+ T cell populations by CD25 and Foxp3 expression as a potential biomarker: reflecting inflammatory activity in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1669–1680. doi:10.2147/COPD.S208977
   PubMed Web of Science ®Google Scholar
• ElTanbouly MA, Noelle RJ. Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nat Rev Immunol. 2021;21(4):257–267. doi:10.1038/s41577-020-00454-2
   PubMed Web of Science ®Google Scholar
• Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10(9):1000–1007. doi:10.1038/ni.1774
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang W, Guo J, Gu Q, Zhu X, Zhou X. Activation and functional specialization of Regulatory T cells lead to the generation of Foxp3 instability. J Immunol. 2017;198(7):2612–2625. doi:10.4049/jimmunol.1601409
   PubMed Web of Science ®Google Scholar
• Feng T, Cao AT, Weaver CT, Elson CO, Cong Y. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis. Gastroenterology. 2011;140(7):2031–2043. doi:10.1053/j.gastro.2011.03.009
   PubMed Web of Science ®Google Scholar
• Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853–1860. doi:10.1038/jid.2011.139
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu T, Cai G, et al. Elevated circulating CD4+ ICOS+ Foxp3+ T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosus. Lupus. 2011;20(6):620–627. doi:10.1177/0961203310392431
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–763. doi:10.1146/annurev.immunol.22.012703.104702
   PubMed Web of Science ®Google Scholar
• van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol. 2018;18(6):363–373. doi:10.1038/s41577-018-0001-y
   PubMed Web of Science ®Google Scholar
• Li L, Liu Y, Chiu C, et al. A regulatory role of chemokine receptor CXCR3 in the pathogenesis of chronic obstructive pulmonary disease and emphysema. Inflammation. 2021;44(3):985–998. doi:10.1007/s10753-020-01393-9
   PubMed Web of Science ®Google Scholar
• Brozyna S, Ahern J, Hodge G, et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. COPD. 2009;6(1):4–16. doi:10.1080/15412550902724164
   PubMedGoogle Scholar
• Smyth LJ, Starkey C, Gordon FS, Vestbo J, Singh D. CD8 chemokine receptors in chronic obstructive pulmonary disease. Clin Exp Immunol. 2008;154(1):56–63. doi:10.1111/j.1365-2249.2008.03729.x
   PubMed Web of Science ®Google Scholar
• Costa C, Traves SL, Tudhope SJ, et al. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. Eur Respir J. 2016;47(4):1093–1102. doi:10.1183/13993003.01642-2015
   PubMed Web of Science ®Google Scholar
• Wang W, Yang X, Luo L, et al. The effects of glucocorticoids and theophylline on CXCR3 expression of peripheral blood T cell in COPD patients (in Chinese). Chinese J Geriatr. 2016;35(11):1196–1200. doi:10.3760/cma.j.issn.0254-9026.2016.11.014
   Google Scholar
• Li Q, Sun J, Cao Y, et al. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. Biomed Pharmacother. 2020;123:109735. doi:10.1016/j.biopha.2019.109735
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Aksoy MO, Georgy M, et al. Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3. Am J Respir Crit Care Med. 2009;179(9):799–805. doi:10.1164/rccm.200807-1089OC
   PubMed Web of Science ®Google Scholar
• Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008;133(1):26–33. doi:10.1378/chest.07-0393
   PubMed Web of Science ®Google Scholar
• Moore TV, Clay BS, Cannon JL, Histed A, Shilling RA, Sperling AI. Inducible costimulator controls migration of T cells to the lungs via down-regulation of CCR7 and CD62L. Am J Respir Cell Mol Biol. 2011;45(4):843–850. doi:10.1165/rcmb.2010-0466OC
   PubMed Web of Science ®Google Scholar
• Cheng LE, Amoura Z, Cheah B, et al. Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis. Arthritis Rheumatol. 2018;70(7):1071–1076. doi:10.1002/art.40479
   PubMed Web of Science ®Google Scholar
• Sullivan BA, Tsuji W, Kivitz A, et al. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci Med. 2016;3(1):e000146. doi:10.1136/lupus-2016-000146
   PubMed Web of Science ®Google Scholar